China grants conditional approval for Merck’s COVID treatment
Molnupiravir, developed by Merck, is approved to be used in adult patients who have mild-to-medium COVID infection and a high risk of progressing to severe cases
China has granted conditional approval for the import of Merck’s COVID-19 treatment Molnupiravir, China’s medical products regulator said today.
Molnupiravir, developed by Merck, is approved to be used in adult patients who have mild-to-medium COVID infection and a high risk of progressing to severe cases, according to China’s National Medical Products Administration.
Edits by EP News Bureau
- Advertisement -
thanks for sharing such a nice information
This article is an appealing wealth of informative data that is interesting and well-written. I commend your hard work on this and thank you for this information.